Since our research records the digestive system malignant tumor sample size too small (includes only 4 RCTs, dapagliflozin group 6 cases, and other active hypoglycemic drugs group 0 cases), difference did not reach statistical significance.
← all excerpts
SGLT-2i and Risk of Malignancy in Type 2 Diabetes: A Meta-Analysis of Randomized Controlled Trials.
1
—
—